Knee osteoarthritis
Conditions
Interventions
Experimental group:A single dose of 0.1 g, 0.1 g/time and 2 times/day was given after 6 hours of fasting
Blank control group:After the 6h fasting period, a placebo with a single dose of 0.1g, and 0.1g / time, 2 times / day beginning the next day
Sponsors
Xi'an Honghui Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) the study is Randomized controlled trial (2)The diagnosis of knee osteoarthritis/osteodystrophy was made by clinical and imaging examinations (3) the study subjects were scheduled to receive primary TKA in adult patients aged 50-80 years (4) American Society of Anesthesiology (ASA) grade 1-2 (5) no contraindication (6) patients agreed to sign the informed consent form
Exclusion criteria
Exclusion criteria: (1) patients with liver and kidney unhealthy history, severe heart and lung disease, severe digestive tract disease and mental disease (2) patients who are allergic to Imrecoxib or anesthetics (3) patients who had taken Imrecoxib or opioids within 2 weeks before operation (4) patients with mental disorders and cognitive impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Range of motion of the knee joint;The consumption of the opioids;C reactive protein, blood sedimentation;Total number of days in hospital; | — |
Countries
China
Contacts
Public ContactBaiGuoYang
Xi'an Honghui Hospital
Outcome results
None listed